Lucid Diagnostics Quote - LUCD

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

0.8499

Bid

0.802

Offer

0.84

Volume

0.00 Day's Range 0.00

0.6301 52 Week Range 1.51

Market Cap

50.435M

Previous Close

0.8499

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

470,885

Shares Outstanding

59,342,479

Dividend Yield

PE Ratio

-0.96

Earnings Per Share (EPS)

-0.89

Revenue

2.43M

Net Profit

-52.67M

Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically hig... Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard. Show more

Sector

Surgical,med Instr,apparatus

Industry

Surgical,med Instr,apparatus

Headquarters

Wilmington, Delaware, USA

Founded

Lucid Diagnostics Inc is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker LUCD. The last closing price for Lucid Diagnostics was US$0.85. Over the last year, Lucid Diagnostics shares have traded in a share price range of US$ 0.6301 to US$ 1.51.

Lucid Diagnostics currently has 59,342,479 shares in issue. The market capitalisation of Lucid Diagnostics is US$50.44 million. Lucid Diagnostics has a price to earnings ratio (PE ratio) of -0.96.

Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume

Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume PR Newswire NEW YORK, Jan. 13, 2025 Quarterly test volume of over 4,000 tests represented sequential increase of 45 percent NEW...

Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule PR Newswire NEW YORK, Dec. 23, 2024 NEW YORK, Dec. 23, 2024 /PRNewswire/ -- Lucid...

Form 8-K - Current report

Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters

Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters PR Newswire NEW YORK, Dec. 19, 2024 Partnership launched with fully-contracted...

Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication

Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication PR Newswire NEW YORK, Dec. 11, 2024 Study demonstrates outstanding...

Form D - Notice of Exempt Offering of Securities

Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones

Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones PR Newswire NEW YORK, Dec. 3, 2024 New convertible debt...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.006	0.710984713829	0.8439	0.88	0.8019	117111	0.84304181	CS
4	0.0856	11.1997906581	0.7643	0.9094	0.7501	254697	0.82477035	CS
12	-0.1501	-15.01	1	1.12	0.7501	470885	0.9054058	CS
26	-0.0001	-0.0117647058824	0.85	1.12	0.7201	324131	0.88168116	CS
52	-0.6201	-42.1836734694	1.47	1.51	0.6301	249356	0.90587501	CS
156	-2.9201	-77.4562334218	3.77	4.0598	0.6301	140512	1.40586271	CS
260	-11.9001	-93.3341176471	12.75	13.5	0.6301	155810	2.52054446	CS

LUCD - Frequently Asked Questions (FAQ)

What is the current Lucid Diagnostics share price?

The current share price of Lucid Diagnostics is US$ 0.8499

How many Lucid Diagnostics shares are in issue?

Lucid Diagnostics has 59,342,479 shares in issue

What is the market cap of Lucid Diagnostics?

The market capitalisation of Lucid Diagnostics is USD 50.44M

What is the 1 year trading range for Lucid Diagnostics share price?

Lucid Diagnostics has traded in the range of US$ 0.6301 to US$ 1.51 during the past year

What is the PE ratio of Lucid Diagnostics?

The price to earnings ratio of Lucid Diagnostics is -0.96

What is the cash to sales ratio of Lucid Diagnostics?

The cash to sales ratio of Lucid Diagnostics is 20.78

What is the reporting currency for Lucid Diagnostics?

Lucid Diagnostics reports financial results in USD

What is the latest annual turnover for Lucid Diagnostics?

The latest annual turnover of Lucid Diagnostics is USD 2.43M

What is the latest annual profit for Lucid Diagnostics?

The latest annual profit of Lucid Diagnostics is USD -52.67M

What is the registered address of Lucid Diagnostics?

The registered address for Lucid Diagnostics is CORPORATION TRUST CENTER 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801

Which industry sector does Lucid Diagnostics operate in?

Lucid Diagnostics operates in the SURGICAL,MED INSTR,APPARATUS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
IPAImmunoPrecise Antibodies Ltd	US$ 0.8059 (63.47%)	9.87M
ADAGAdagene Inc	US$ 2.50 (41.08%)	3
NEHCNew Era Helium Inc	US$ 3.86 (40.88%)	1.4M
CDIOCardio Diagnostics Holdings Inc	US$ 0.823 (35.36%)	7.57M
ASSTAsset Entities Inc	US$ 1.17 (30.00%)	6.6M
ABLAbacus Life Inc	US$ 3.01 (-59.97%)	31
IZTCInvizyne Technologies Inc	US$ 7.02 (-37.88%)	7
ARTVArtiva Biotherapeutics Inc	US$ 5.31 (-24.89%)	2
HTLMHomesToLife Ltd	US$ 5.97 (-23.66%)	10
TMCITreace Medical Concepts Inc	US$ 7.23 (-22.01%)	11
IPAImmunoPrecise Antibodies Ltd	US$ 0.8059 (63.47%)	9.87M
CDIOCardio Diagnostics Holdings Inc	US$ 0.823 (35.36%)	7.57M
ASSTAsset Entities Inc	US$ 1.17 (30.00%)	6.6M
RIMEAlgorhythm Holdings Inc	US$ 0.0381 (10.12%)	6.4M
SHViShares Short Treasury Bond ETF	US$ 110.36 (0.00%)	3.56M